Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China
- PMID: 19064562
- PMCID: PMC2760732
- DOI: 10.1158/1055-9965.EPI-08-0517
Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China
Abstract
CYP19A1 encodes for aromatase, which irreversibly converts androgens to estrogens; variation in this gene may affect individual susceptibility to breast cancer and other sex hormone-dependent outcomes. In a case-control study nested within a breast self-examination trial conducted in China, we examined whether CYP19A1 polymorphisms (rs1870049, rs1004982, rs28566535, rs936306, rs11636639, rs767199, rs4775936, rs11575899, rs10046, and rs4646) were associated with risk of breast cancer and fibrocystic breast conditions. Cases were diagnosed with breast cancer (n = 614) or fibrocystic breast conditions (n = 465) during 1989 to 2000. Controls were free of breast disease during the same period (n = 879). Presence of proliferative changes within the extratumoral tissue of women with breast cancer and the lesions of women with fibrocystic conditions only was assessed. None of the polymorphisms were associated with overall risk of breast cancer or fibrocystic breast conditions. Differences in breast cancer risk, however, were observed by proliferation status. The risk of breast cancer with (but not without) proliferative fibrocystic conditions was increased among women homozygous for the minor allele of rs1004982 (C), rs28566535 (C), rs936306 (T), and rs4775936 (C) relative to those homozygous for the major allele [age-adjusted odds ratios (95% confidence intervals), 2.19 (1.24-3.85), 2.20 (1.27-3.82), 1.94 (1.13-3.30), and 1.95 (1.07-3.58), respectively]. Also, haplotypes inferred using all polymorphisms were not associated with overall risk of either outcome, although some block-specific haplotypes were associated with an increased risk of breast cancer with concurrent proliferative fibrocystic conditions. Our findings suggest that CYP19A1 variation may enhance breast cancer development in some women, but further confirmation is warranted.
Figures
Similar articles
-
Selected estrogen receptor 1 and androgen receptor gene polymorphisms in relation to risk of breast cancer and fibrocystic breast conditions among Chinese women.Cancer Epidemiol. 2011 Feb;35(1):48-55. doi: 10.1016/j.canep.2010.08.005. Epub 2010 Sep 17. Cancer Epidemiol. 2011. PMID: 20846920 Free PMC article. Clinical Trial.
-
Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women.Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1066-73. doi: 10.1158/1055-9965.EPI-07-2680. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18483327 Free PMC article.
-
Glutathione S-transferase M1 and P1 polymorphisms and risk of breast cancer and fibrocystic breast conditions in Chinese women.Breast Cancer Res Treat. 2008 May;109(1):143-55. doi: 10.1007/s10549-007-9633-5. Epub 2007 Jul 12. Breast Cancer Res Treat. 2008. PMID: 17624589 Free PMC article.
-
Association between rs10046, rs1143704, rs767199, rs727479, rs1065778, rs1062033, rs1008805, and rs700519 polymorphisms in aromatase (CYP19A1) gene and Alzheimer's disease risk: a systematic review and meta-analysis involving 11,051 subjects.Neurol Sci. 2019 Dec;40(12):2515-2527. doi: 10.1007/s10072-019-04003-1. Epub 2019 Jul 5. Neurol Sci. 2019. PMID: 31278540
-
Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.BMC Med. 2015 Jun 11;13:139. doi: 10.1186/s12916-015-0373-9. BMC Med. 2015. PMID: 26067721 Free PMC article.
Cited by
-
Associations between aromatase CYP19 rs10046 polymorphism and breast cancer risk: from a case-control to a meta-analysis of 20,098 subjects.PLoS One. 2013;8(1):e53902. doi: 10.1371/journal.pone.0053902. Epub 2013 Jan 16. PLoS One. 2013. PMID: 23342035 Free PMC article.
-
Functional variable number of tandem repeats variation in the promoter of proto-oncogene PTTG1IP is associated with risk of estrogen receptor-positive breast cancer.Cancer Sci. 2012 Jun;103(6):1121-8. doi: 10.1111/j.1349-7006.2012.02266.x. Epub 2012 Apr 12. Cancer Sci. 2012. PMID: 22404099 Free PMC article.
-
Associations between CYP19A1 polymorphisms, Native American ancestry, and breast cancer risk and mortality: the Breast Cancer Health Disparities Study.Cancer Causes Control. 2014 Nov;25(11):1461-71. doi: 10.1007/s10552-014-0448-5. Epub 2014 Aug 5. Cancer Causes Control. 2014. PMID: 25088806 Free PMC article.
-
Genetic variants in hormone-related genes and risk of breast cancer.PLoS One. 2013 Jul 23;8(7):e69367. doi: 10.1371/journal.pone.0069367. Print 2013. PLoS One. 2013. PMID: 23935996 Free PMC article.
-
Analysis of the rs10046 polymorphism of aromatase (CYP19) in premenopausal onset of human breast cancer.Int J Mol Sci. 2014 Jan 7;15(1):712-24. doi: 10.3390/ijms15010712. Int J Mol Sci. 2014. PMID: 24402127 Free PMC article.
References
-
- Henderson BE, Ross RK, Pike MC, Casagrande JT. Endogenous hormones as a major factor in human cancer. Cancer Res. 1982;42:3232–3239. - PubMed
-
- Thomas HV, Reeves GK, Key TJ. Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control. 1997;8:922–928. - PubMed
-
- Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1998;90:1292–1299. - PubMed
-
- Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D. Estrogens as endogenous genotoxic agents--DNA adducts and mutations. J Natl Cancer Inst Monographs. 2000:75–93. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical